Sprint Bioscience ABOSTO:SPRINT +0.25%32 PB Ratio is 4.04 as of Jul. 03, 2026, which is 3% below its 10-year median of 4.17. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Sprint Bioscience AB ranks worse than 62.13% on this metric.
The historical rank and industry rank for Sprint Bioscience AB's PB Ratio or its related term are showing as below:
OSTO:SPRINT'
s PB Ratio Range Over the Past 10 Years
Min: 0.93 Med: 4.17 Max: 124.72
Current: 4.03
During the past 13 years, Sprint Bioscience AB's highest PB Ratio was 124.72. The lowest was 0.93. And the median was 4.17.
OSTO:SPRINT's PB Ratio is ranked worse than 62.13% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs OSTO:SPRINT: 4.03
During the past 12 months, Sprint Bioscience AB's average Book Value Per Share Growth Rate was 1874.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 41.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sprint Bioscience AB was 97.70% per year. The lowest was -55.40% per year. And the median was 5.25% per year.
Back to Basics: PB Ratio
Sprint Bioscience AB (OSTO:SPRINT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sprint Bioscience AB PB Ratio Related Terms
Sprint Bioscience AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sprint Bioscience AB (OSTO:SPRINT) has a PB Ratio of 4.04 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sprint Bioscience AB and its competitors. This is near median its historical median of 4.17. Over the past decade, Sprint Bioscience AB's PB Ratio has ranged from 0.93 to 124.72. According to the industry distribution chart, Sprint Bioscience AB ranks #763 out of 1228 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Sprint Bioscience AB's PB Ratio too high?
Sprint Bioscience AB's current PB Ratio of 4.04 is near median its 10-year median of 4.17. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 124.72. The Biotechnology industry median PB Ratio is 2.97. Sprint Bioscience AB's value of 4.04 is 36% above this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #763 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #763 out of 1228 companies for PB Ratio. This places Sprint Bioscience AB in the lower half of its industry. The industry median PB Ratio is 2.97. Sprint Bioscience AB's value of 4.04 is 36% above this benchmark. Historically, Sprint Bioscience AB's own PB Ratio has ranged from 0.93 to 124.72 over the past decade. While the company's 10-year median is 4.17 vs. the industry median of 2.97, Sprint Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current PB Ratio of 4.04 is 36% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current PB Ratio is 4.04, which is near median its own 10-year median of 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.07 — trading 86.7% above its estimated fair value. The current PB Ratio is 4.04, which is near median its 10-year median of 4.17 and 36% above the Biotechnology industry median of 2.97. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current PB Ratio is 4.04 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.07 is trading 86.7% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
PB Ratio: 4.04 (near median its 10-year median of 4.17)
GF Value™: kr2.18 vs. price of kr4.07 (86.7% above fair value)
Industry Position: 36% above the Biotechnology median (#763 of 1228)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
